<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035137</url>
  </required_header>
  <id_info>
    <org_study_id>N2011-01</org_study_id>
    <nct_id>NCT02035137</nct_id>
  </id_info>
  <brief_title>131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat</brief_title>
  <acronym>N2011-01</acronym>
  <official_title>NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Approaches to Neuroblastoma Therapy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Approaches to Neuroblastoma Therapy Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG)
      and compare their effects on tumor response and associated side effects, to determine if one
      therapy is better than the other for people diagnosed with relapsed or persistent
      neuroblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>43-50 days from study day 1</time_frame>
    <description>To identify the MIBG treatment regimen associated with the highest overall response rate after one course of treatment on the following three arms: single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Delayed engraftment</measure>
    <time_frame>43-71 days after study day 1.</time_frame>
    <description>To compare toxicity profiles associated with occurence of delayed engraftment defined as failure to achieve ANC &gt;= 500/uL by day 43 and platelet count &gt;= 20,000 by day 71 of protocol therapy in absence of progressive bone marrow metastatic disease for each of the following 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of toxic death</measure>
    <time_frame>Days 43 to 50 after study day 1</time_frame>
    <description>To compare the occurence of toxic deaths for each of the following 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or greater non-hematologic toxicities</measure>
    <time_frame>day 43 - 50 after study day 1</time_frame>
    <description>Compare toxicity profiles for grade 3 or greater toxicities associated with each of 131I-MIBG treatment regimens; single-agent 131I-MIBG; Vincristine/Irinotecan/131I-MIBG; or Vorinostat/131I-MIBG</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Single-Agent 131I-MIBG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single-agent 131I-MIBG (Arm A) 18 mCi/kg 131I-MIBG on Day 1 and autologous stem cell infusion on Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>131I-MIBG with Vincristine/Irinotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vincristine / irinotecan / 131I-MIBG (Arm B): vincristine 2 mg/m2 (maximum dose 2 mg) intravenously on Day 0; irinotecan 50 mg/m2 (maximum dose 100 mg) intravenously on Days 0 to 4. Patients will also receive diarrhea prophylaxis with cefixime 8 mg/kg/day orally on Days -1 to +6. 31I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>131I-MIBG with Vorinostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vorinostat / 131I-MIBG (Arm C); vorinostat 180 mg/m2 (maximum dose 400 mg) orally once daily on Days -1 to +12 (14 total doses). 131I-MIBG, 18 mCi/kg on Day 1 and autologous stem cell infusion on Day 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>131I-MIBG</intervention_name>
    <arm_group_label>Single-Agent 131I-MIBG</arm_group_label>
    <arm_group_label>131I-MIBG with Vincristine/Irinotecan</arm_group_label>
    <arm_group_label>131I-MIBG with Vorinostat</arm_group_label>
    <other_name>131I-Metaiodobenzylguanidine</other_name>
    <other_name>Iobenguane sulfate</other_name>
    <other_name>m-Iodobenzylguanidine sulfate</other_name>
    <other_name>MIBG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <arm_group_label>131I-MIBG with Vincristine/Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>131I-MIBG with Vincristine/Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat</intervention_name>
    <arm_group_label>131I-MIBG with Vorinostat</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be &gt; 24 months and &lt; 30 years of age when registered on study.

          -  Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than
             a partial response to standard treatment or persistent neuroblastoma that had at least
             a partial response to frontline therapy frontline therapy with &gt; 3 residual lesions on
             end-induction MIBG scan.

          -  Patients must have evidence of MIBG uptake into tumor at â‰¥ one site within 4 weeks
             prior to entry on study and subsequent to any intervening therapy.

          -  Patients must have adequate heart, kidney, liver and bone marrow function. Patients
             who have bone marrow disease must still have adequate bone marrow function to enter
             the study.

          -  Patients must have a dose of unpurged peripheral blood stem cells is 2.0 x 106 viable
             CD34+ cells/kg available.

        Exclusion Criteria:

          -  They have had previous I-131 MIBG therapy

          -  They have other medical problems that could get much worse with this treatment.

          -  They are pregnant or breast feeding.

          -  They have a history of a venous or arterial thrombosis that was not associated to a
             central line.

          -  They have active infections such as hepatitis or fungal infections.

          -  They have active diarhhea.

          -  They have had an allogeneic stem cell transplant (received stem cell from someone
             else)

          -  They can't cooperate with the special precautions that are needed for this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven DuBois, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Childrens Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Salter Packer Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago, Comer Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Healthcare System</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

